Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the gastroenterology disease testing capabilities of Mayo Clinic Laboratories, including:
BioPharma Diagnostics partners can access gastroenterology testing for clinical trials and be among the first to use up-and-coming tests currently in development.
The latest
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.
In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.
In this month's "Hot Topic," Alicia Algeciras, Ph.D., DABCC, and Joshua Bornhorst, Ph.D., DABCC, discuss Alzheimer's disease CSF biomarkers.
Director of Mayo Clinic’s Infectious Diseases Serology Laboratory, Elitza Theel, Ph.D., joins a discussion about COVID-19 antibody testing in a recent story on NPR.
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gastroenterology Pathology and Surgical Pathology.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gastroenterology Pathology and Surgical Pathology.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
Puanani Hopson, D.O., a Mayo Clinic pediatric gastroenterologist, explains the pancreatic elastase test — a screening test that can be useful when symptoms point to the possibility of exocrine pancreatic insufficiency. Dr. Hopson reviews when this test should be ordered, how it compares to other test options, and how its results can guide further evaluation.